DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination

James Brophy; Gregory Henkle; Eric M. Rohren

doi:10.1097/RLU.0000000000003847

DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination

James Brophy, Gregory Henkle, Eric M. Rohren

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

A 58-year-old man underwent DOTATATE PET/CT scan for follow-up of pulmonary neuroendocrine tumor after resection and adjuvant chemotherapy. On screening paperwork, the patient indicated having received the Johnson & Johnson/Janssen COVID-19 vaccine (Janssen Biotech, Inc) 1 day previously, administered in the right deltoid muscle. Reactive changes in regional lymph nodes is a known response for all 3 currently Food and Drug Administration-approved COVID-19 vaccines. Recent published data have demonstrated FDG PET-avid axillary lymphadenopathy subsequent to COVID-19 vaccination, and included here is a report of DOTATATE PET-avid axillary lymph node after injection of the Johnson & Johnson COVID-19 vaccine.

Original language	English (US)
Pages (from-to)	174-175
Number of pages	2
Journal	Clinical Nuclear Medicine
Volume	47
Issue number	2
DOIs	https://doi.org/10.1097/RLU.0000000000003847
State	Published - Feb 1 2022

Keywords

COVID-19
DOTATATE
PET
lymphadenopathy
Humans
Middle Aged
Vaccination
Male
Positron-Emission Tomography
Lymph Nodes
Positron Emission Tomography Computed Tomography
SARS-CoV-2
COVID-19 Vaccines
Radionuclide Imaging
Fluorodeoxyglucose F18

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000003847

Cite this

@article{26ae66c9aa514c298d0e693abbd399c3,

title = "DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination",

abstract = "A 58-year-old man underwent DOTATATE PET/CT scan for follow-up of pulmonary neuroendocrine tumor after resection and adjuvant chemotherapy. On screening paperwork, the patient indicated having received the Johnson & Johnson/Janssen COVID-19 vaccine (Janssen Biotech, Inc) 1 day previously, administered in the right deltoid muscle. Reactive changes in regional lymph nodes is a known response for all 3 currently Food and Drug Administration-approved COVID-19 vaccines. Recent published data have demonstrated FDG PET-avid axillary lymphadenopathy subsequent to COVID-19 vaccination, and included here is a report of DOTATATE PET-avid axillary lymph node after injection of the Johnson & Johnson COVID-19 vaccine.",

keywords = "COVID-19, DOTATATE, PET, lymphadenopathy, Humans, Middle Aged, Vaccination, Male, Positron-Emission Tomography, Lymph Nodes, Positron Emission Tomography Computed Tomography, SARS-CoV-2, COVID-19 Vaccines, Radionuclide Imaging, Fluorodeoxyglucose F18",

author = "James Brophy and Gregory Henkle and Rohren, {Eric M.}",

year = "2022",

month = feb,

day = "1",

doi = "10.1097/RLU.0000000000003847",

language = "English (US)",

volume = "47",

pages = "174--175",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

TY - JOUR

T1 - DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination

AU - Brophy, James

AU - Henkle, Gregory

AU - Rohren, Eric M.

PY - 2022/2/1

Y1 - 2022/2/1

N2 - A 58-year-old man underwent DOTATATE PET/CT scan for follow-up of pulmonary neuroendocrine tumor after resection and adjuvant chemotherapy. On screening paperwork, the patient indicated having received the Johnson & Johnson/Janssen COVID-19 vaccine (Janssen Biotech, Inc) 1 day previously, administered in the right deltoid muscle. Reactive changes in regional lymph nodes is a known response for all 3 currently Food and Drug Administration-approved COVID-19 vaccines. Recent published data have demonstrated FDG PET-avid axillary lymphadenopathy subsequent to COVID-19 vaccination, and included here is a report of DOTATATE PET-avid axillary lymph node after injection of the Johnson & Johnson COVID-19 vaccine.

AB - A 58-year-old man underwent DOTATATE PET/CT scan for follow-up of pulmonary neuroendocrine tumor after resection and adjuvant chemotherapy. On screening paperwork, the patient indicated having received the Johnson & Johnson/Janssen COVID-19 vaccine (Janssen Biotech, Inc) 1 day previously, administered in the right deltoid muscle. Reactive changes in regional lymph nodes is a known response for all 3 currently Food and Drug Administration-approved COVID-19 vaccines. Recent published data have demonstrated FDG PET-avid axillary lymphadenopathy subsequent to COVID-19 vaccination, and included here is a report of DOTATATE PET-avid axillary lymph node after injection of the Johnson & Johnson COVID-19 vaccine.

KW - COVID-19

KW - DOTATATE

KW - PET

KW - lymphadenopathy

KW - Humans

KW - Middle Aged

KW - Vaccination

KW - Male

KW - Positron-Emission Tomography

KW - Lymph Nodes

KW - Positron Emission Tomography Computed Tomography

KW - SARS-CoV-2

KW - COVID-19 Vaccines

KW - Radionuclide Imaging

KW - Fluorodeoxyglucose F18

UR - http://www.scopus.com/inward/record.url?scp=85123187044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123187044&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000003847

DO - 10.1097/RLU.0000000000003847

M3 - Article

C2 - 34269723

AN - SCOPUS:85123187044

SN - 0363-9762

VL - 47

SP - 174

EP - 175

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 2

ER -

DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this